Morgan Stanley’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-732,328
| Closed | -$20.5M | – | 8287 |
|
|
2022
Q1 | $20.5M | Sell |
732,328
-42,046
| -5% | -$1.15M | ﹤0.01% | 2083 |
|
|
2021
Q4 | $21.1M | Buy |
774,374
+51,138
| +7% | +$1.39M | ﹤0.01% | 2084 |
|
|
2021
Q3 | $19.7M | Buy |
723,236
+557,051
| +335% | +$13.8M | ﹤0.01% | 2104 |
|
|
2021
Q2 | $2.84M | Buy |
166,185
+1,718
| +1% | +$32.2K | ﹤0.01% | 4342 |
|
|
2021
Q1 | $3.44M | Sell |
164,467
-8,618
| -5% | -$199K | ﹤0.01% | 3796 |
|
|
2020
Q4 | $3.96M | Buy |
173,085
+159,111
| +1,139% | +$3.03M | ﹤0.01% | 3510 |
|
|
2020
Q3 | $228K | Sell |
13,974
-10,169
| -42% | -$184K | ﹤0.01% | 5038 |
|
|
2020
Q2 | $327K | Sell |
24,143
-14,483
| -37% | -$169K | ﹤0.01% | 4826 |
|
|
2020
Q1 | $458K | Sell |
38,626
-346,340
| -90% | -$7.68M | ﹤0.01% | 4429 |
|
|
2019
Q4 | $9.59M | Sell |
384,966
-230,024
| -37% | -$4.66M | ﹤0.01% | 2475 |
|
|
2019
Q3 | $10.5M | Buy |
614,990
+112,392
| +22% | +$2.05M | ﹤0.01% | 2076 |
|
|
2019
Q2 | $11.4M | Sell |
502,598
-117,784
| -19% | -$3.18M | ﹤0.01% | 2011 |
|
|
2019
Q1 | $19.9M | Buy |
620,382
+176,901
| +40% | +$5.47M | 0.01% | 1445 |
|
|
2018
Q4 | $12.5M | Buy |
443,481
+208,831
| +89% | +$6.12M | ﹤0.01% | 1879 |
|
|
2018
Q3 | $6.75M | Buy |
234,650
+130,847
| +126% | +$3.93M | ﹤0.01% | 2851 |
|
|
2018
Q2 | $3.89M | Sell |
103,803
-15,861
| -13% | -$623K | ﹤0.01% | 3437 |
|
|
2018
Q1 | $4.7M | Sell |
119,664
-19,200
| -14% | -$701K | ﹤0.01% | 3087 |
|
|
2017
Q4 | $4.5M | Sell |
138,864
-74,075
| -35% | -$2.22M | ﹤0.01% | 3219 |
|
|
2017
Q3 | $6.63M | Sell |
212,939
-96,123
| -31% | -$2.84M | ﹤0.01% | 2669 |
|
|
2017
Q2 | $8.64M | Sell |
309,062
-293,437
| -49% | -$6.64M | ﹤0.01% | 2312 |
|
|
2017
Q1 | $10.3M | Buy |
602,499
+27,550
| +5% | +$386K | ﹤0.01% | 2159 |
|
|
2016
Q4 | $6.96M | Buy |
574,949
+83,106
| +17% | +$1.08M | ﹤0.01% | 2649 |
|
|
2016
Q3 | $7.79M | Buy |
491,843
+9,264
| +2% | +$140K | ﹤0.01% | 2236 |
|
|
2016
Q2 | $6.24M | Buy |
482,579
+164,383
| +52% | +$2.57M | ﹤0.01% | 2403 |
|
|
2016
Q1 | $6.05M | Buy |
318,196
+9,349
| +3% | +$169K | ﹤0.01% | 2343 |
|
|
2015
Q4 | $6.95M | Buy |
308,847
+233,353
| +309% | +$4.61M | ﹤0.01% | 2341 |
|
|
2015
Q3 | $1.77M | Buy |
75,494
+55,926
| +286% | +$1.54M | ﹤0.01% | 3633 |
|
|
2015
Q2 | $560K | Sell |
19,568
-54,075
| -73% | -$1.42M | ﹤0.01% | 4638 |
|
|
2015
Q1 | $1.9M | Sell |
73,643
-102,194
| -58% | -$2.34M | ﹤0.01% | 3626 |
|
|
2014
Q4 | $3.26M | Buy |
175,837
+126,791
| +259% | +$2.28M | ﹤0.01% | 3132 |
|
|
2014
Q3 | $760K | Buy |
+49,046
| New | +$738K | ﹤0.01% | 4270 |
|
Morgan Stanley's XENT Position: Q2 2022 in Review
Morgan Stanley sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 732,328 shares — an estimated $20.5M sold.
Morgan Stanley first reported a position in XENT in Q3 2014 and held it in 31 quarters. The position peaked at $21.1M in Q4 2021. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- Morgan Stanley reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- Morgan Stanley sold 732,328 Intersect ENT, Inc shares in Q2 2022, an estimated $20.5M.
- Morgan Stanley first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 31 quarters.
- Morgan Stanley's Intersect ENT, Inc position peaked at $21.1M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on Morgan Stanley's 13F filing for Q2 2022, filed 15 Aug 2022.